I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Burt Adelman Biography and Net Worth

Director of Verve Therapeutics

Burt Adelman is a thought leader and expert in drug development with more than 25 years of experience in the biotech industry. He was most recently executive vice president and chief medical officer at Dyax Corp., where he led the development of lanadelumab (Takhzyro), approved by the FDA and EMA for the prophylactic treatment of hereditary angioedema. Dyax was acquired by Shire in 2016. Dr. Adelman began his career at Biogen where he had an unparalleled track record, having led the successful development of important biologic therapeutics including Angiomax®, Avonex®, Amevive® and Tysabri®. At Biogen, he served in various roles including vice president of regulatory affairs, executive vice president of R&D, and executive vice president of portfolio strategy. Dr. Adelman is a member of the board of directors of Catabasis, Sirona, Clear Creek Bio, and Syntimmune, until it was sold to Alexion in 2018. He is also special advisor at Novo Ventures (US) Inc. He graduated from Cornell University Medical College, served as House Officer and Medical Resident at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital) and Harvard Medical School, and completed his hematology fellowship at Brigham and Women’s Hospital (BWH). Dr. Adelman is a member of the Tufts Medical School Board of Overseers, an advisor to the Boston Biomedical Innovation Center at BWH, and a member of the investment committee of the Partners Innovation Fund (Mass General Hospital and BWH).

What is Burt A. Adelman's net worth?: The estimated net worth of Burt A. Adelman is at least $103,411.00 as of May 12th, 2022. Dr. Adelman owns 18,700 shares of Verve Therapeutics stock worth more than $103,411 as of December 18th. This net worth estimate does not reflect any other assets that Dr. Adelman may own. Learn More about Burt A. Adelman's net worth.
How do I contact Burt A. Adelman?: The corporate mailing address for Dr. Adelman and other Verve Therapeutics executives is , , . Verve Therapeutics can also be reached via phone at 617-603-0070 and via email at [email protected]. Learn More on Burt A. Adelman's contact information.
Has Burt A. Adelman been buying or selling shares of Verve Therapeutics?: Burt A. Adelman has not been actively trading shares of Verve Therapeutics over the course of the past ninety days. Most recently, on Thursday, May 12th, Burt A. Adelman bought 10,000 shares of Verve Therapeutics stock. The stock was acquired at an average cost of $12.15 per share, with a total value of $121,500.00. Following the completion of the transaction, the director now directly owns 18,700 shares of the company's stock, valued at $227,205. Learn More on Burt A. Adelman's trading history.
Who are Verve Therapeutics' active insiders?: Verve Therapeutics' insider roster includes Burt Adelman (Director), Andrew Ashe (Insider), Andrew Bellinger (Insider), and Sekar Kathiresan (CEO). Learn More on Verve Therapeutics' active insiders.
Are insiders buying or selling shares of Verve Therapeutics?: In the last twelve months, Verve Therapeutics insiders bought shares 1 times. They purchased a total of 76,000 shares worth more than $475,760.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 1,514 shares worth more than $12,475.36. The most recent insider tranaction occured on May, 14th when insider Andrew D Ashe bought 76,000 shares worth more than $475,760.00. Insiders at Verve Therapeutics own 19.3% of the company. Learn More about insider trades at Verve Therapeutics.
Information on this page was last updated on 5/14/2024.

Burt A. Adelman Insider Trading History at Verve Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/12/2022	Buy	10,000	$12.15	$121,500.00	18,700
3/15/2022	Buy	4,000	$21.38	$85,520.00
12/2/2021	Buy	4,700	$31.34	$147,298.00

Burt A. Adelman Buying and Selling Activity at Verve Therapeutics

Verve Therapeutics Company Overview

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $5.09

$5.05

$5.59

50 Day Range

MA: $5.75

$4.50

$7.19

2 Week Range

Now: $5.09

$4.30

$19.34

Volume

2,051,953 shs

Average Volume

1,361,526 shs

Market Capitalization

$430.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

This Crypto Is Set to Explode in December

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW